Key facts
- HkeyBio launched a new preclinical disease model platform.
- The platform covers Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN).
- It integrates standardized rodent models with AI and other technologies.
- The platform aims to enable a 'one drug, multiple screens' approach in autoimmune drug R&D.
HkeyBio announced on June 3, 2026, the launch of its new preclinical disease model platform designed for autoimmune disease research and development. The platform integrates standardized rodent models with artificial intelligence (AI) and other advanced technologies. It specifically targets Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This comprehensive approach is intended to facilitate a "one drug, multiple screens" strategy, aiming to expedite the discovery and development of new drugs for these autoimmune conditions.